SCHEMBL23979133

SCHEMBL23979133

CCOC(=O)[C@@H](N)CNC(=O)N(C)Cc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.50
NPC1 O15118 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.48
ALDH1A1 P00352 2/20 0.45
LMNA P02545 1/20 0.45
POLB P06746 1/20 0.45
HSD17B10 Q99714 1/20 0.45
ABCC1 P33527 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KMT2A Q03164 1/20 0.43
CA12 O43570 1/20 0.43
CA9 Q16790 1/20 0.43
HTT P42858 1/20 0.43
CHRNB2 P17787 1/20 0.42
CHRNB4 P30926 1/20 0.42
CHRNA3 P32297 1/20 0.42
CHRNA4 P43681 1/20 0.42
MTOR P42345 1/20 0.42
MMP8 P22894 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24804261 1.00 RAB9A (0.50) RAB9ANPC1L3MBTL1ALDH1A1LMNA
SCHEMBL23978750 0.90 ABCC1 (0.47) RAB9ANPC1ALDH1A1LMNAABCC1
SCHEMBL24803337 0.90 ABCC1 (0.47) RAB9ANPC1ALDH1A1LMNAABCC1
SCHEMBL29019144 0.85 NPC1 (0.53) RAB9ANPC1ABCC1KMT2ACA12
SCHEMBL967460 0.76 NPC1 (0.62) RAB9ANPC1ABCC1SMN1; SMN2KMT2A
SCHEMBL23978669 0.75 MEN1 (0.50) RAB9ANPC1ALDH1A1LMNAABCC1
SCHEMBL23979013 0.74 NPC1 (0.53) RAB9ANPC1ABCC1KMT2ACA12
SCHEMBL6445175 0.74 PSMB1 (0.49) RAB9ANPC1ALDH1A1ABCC1KMT2A
SCHEMBL23978751 0.73 NPC1 (0.51) RAB9ANPC1ALDH1A1ABCC1KMT2A
SCHEMBL132409 0.73 ALPI (0.61) NPC1ALDH1A1KMT2AMMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11643388-B2 Inhibitors of alpha 2 beta 1 integrin and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-05-09 US disclosed
WO-2021222789-A1 INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11643388-B2 Inhibitors of alpha 2 beta 1 integrin and methods of use thereof ITGB1, ITGB2, ITGA2 RAB9A 1856/4885NPC1 2492/4885L3MBTL1 1336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.